Genentech
Genentech articles from Informachine.Genentech rejects Roche’s $43.7-billion takeover offer as too low
13 Aug 2008
Biotechnology giant Genentech Inc today rejected a $43.7-billion takeover bid from its majority shareholder, Roche Holding AG, as too low, while saying it would be open to a higher proposal.
Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.
Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!
Latest articles on Genentech from Informachine
Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-Positive Early-Stage Breast Cancer
10 Dec 2025
Discover the latest news about our company, our products, our policies, and our people.
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
10 Dec 2025
Discover the latest news about our company, our products, our policies, and our people.
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
18 Nov 2025
Discover the latest news about our company, our products, our policies, and our people.
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
10 Nov 2025
Discover the latest news about our company, our products, our policies, and our people.
Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
28 Oct 2025
Discover the latest news about our company, our products, our policies, and our people.
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
22 Oct 2025
Discover the latest news about our company, our products, our policies, and our people.
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
22 Oct 2025
Discover the latest news about our company, our products, our policies, and our people.
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
22 Oct 2025
Discover the latest news about our company, our products, our policies, and our people.
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
22 Oct 2025
Discover the latest news about our company, our products, our policies, and our people.
Genentech Expands Xofluza
17 Oct 2025
Discover the latest news about our company, our products, our policies, and our people.
.webp)
